Protocol AIS-D04: A Phase 1b, Open-label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects with Autoimmune Cytopenias
Povetacicept (ALPN-303) is a dual BAFF/APRIL antagonist
Primary immune thrombocytopenia, warm autoimmune hemolytic anemia, or cold agglutinin disease after failure of at least 2 treatment regimens.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
Babylon Medical Oncology
Brooklyn Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology
Contact us today to request an appointment.Virtual & Telemedicine available.
Learn more news and information related to COVID-19.